Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishimura T, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Tanaka H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Ueda Y, Kim SK, Tada F, Nakamura S, Matsuura T, Nakamura Y, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Koshiyama Y, Kanayama Y, Noritake H, Okamura J, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T, RELPEC Group and HCC 48 Group

Open source

DOI: 10.1111/hepr.70115
Published: 2026 May
Container: Hepatology research : the official journal of the Japan Society of Hepatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/hepr.70115,
  title = {Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.},
  author = {Ohama H and Hiraoka A and Tada T and Hirooka M and Kariyama K and Tani J and Atsukawa M and Takaguchi K and Itobayashi E and Fukunishi S and Nishimura T and Tsuji K and Ishikawa T and Tajiri K and Toyoda H and Ogawa C and Hatanaka T and Kakizaki S and Kawata K and Naganuma A and Kosaka H and Matono T and Kuroda H and Yata Y and Nishikawa H and Tanaka H and Imai M and Aoki T and Ochi H and Tamai H and Komatsu S and Ueda Y and Kim SK and Tada F and Nakamura S and Matsuura T and Nakamura Y and Yoshida O and Nouso K and Morishita A and Itokawa N and Okubo T and Arai T and Tsutsui A and Nagano T and Tanaka K and Koshiyama Y and Kanayama Y and Noritake H and Okamura J and Enomoto H and Matsui K and Kaibori M and Fukumoto T and Hiasa Y and Kudo M and Kumada T and RELPEC Group and HCC 48 Group},
  year = {2026},
  journal = {Hepatology research : the official journal of the Japan Society of Hepatology},
  doi = {10.1111/hepr.70115},
  url = {https://doi.org/10.1111/hepr.70115}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.
AU  - Ohama H
AU  - Hiraoka A
AU  - Tada T
AU  - Hirooka M
AU  - Kariyama K
AU  - Tani J
AU  - Atsukawa M
AU  - Takaguchi K
AU  - Itobayashi E
AU  - Fukunishi S
AU  - Nishimura T
AU  - Tsuji K
AU  - Ishikawa T
AU  - Tajiri K
AU  - Toyoda H
AU  - Ogawa C
AU  - Hatanaka T
AU  - Kakizaki S
AU  - Kawata K
AU  - Naganuma A
AU  - Kosaka H
AU  - Matono T
AU  - Kuroda H
AU  - Yata Y
AU  - Nishikawa H
AU  - Tanaka H
AU  - Imai M
AU  - Aoki T
AU  - Ochi H
AU  - Tamai H
AU  - Komatsu S
AU  - Ueda Y
AU  - Kim SK
AU  - Tada F
AU  - Nakamura S
AU  - Matsuura T
AU  - Nakamura Y
AU  - Yoshida O
AU  - Nouso K
AU  - Morishita A
AU  - Itokawa N
AU  - Okubo T
AU  - Arai T
AU  - Tsutsui A
AU  - Nagano T
AU  - Tanaka K
AU  - Koshiyama Y
AU  - Kanayama Y
AU  - Noritake H
AU  - Okamura J
AU  - Enomoto H
AU  - Matsui K
AU  - Kaibori M
AU  - Fukumoto T
AU  - Hiasa Y
AU  - Kudo M
AU  - Kumada T
AU  - RELPEC Group and HCC 48 Group
PY  - 2026
JO  - Hepatology research : the official journal of the Japan Society of Hepatology
DO  - 10.1111/hepr.70115
UR  - https://doi.org/10.1111/hepr.70115
ER  -

APA

H, O., A, H., T, T., M, H., K, K., J, T., M, A., K, T., E, I., S, F., T, N., K, T., T, I., K, T., H, T., C, O., T, H., S, K., K, K., A, N., H, K., T, M., H, K., Y, Y., H, N., H, T., M, I., T, A., H, O., H, T., S, K., Y, U., SK, K., F, T., S, N., T, M., Y, N., O, Y., K, N., A, M., N, I., T, O., T, A., A, T., T, N., K, T., Y, K., Y, K., H, N., J, O., H, E., K, M., M, K., T, F., Y, H., M, K., T, K., & Group, R. G. A. H. 4. (2026). Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.. Hepatology research : the official journal of the Japan Society of Hepatology. https://doi.org/10.1111/hepr.70115

Source records

pubmed · retrieved 2026-09-27T07:15:47.122Z